[go: up one dir, main page]

EA200000836A1 - Применение n-замещенных 1,5-дидезокси-1,5-имино-d-глюцитных производных для лечения инфекций, вызываемых вирусами гепатита - Google Patents

Применение n-замещенных 1,5-дидезокси-1,5-имино-d-глюцитных производных для лечения инфекций, вызываемых вирусами гепатита

Info

Publication number
EA200000836A1
EA200000836A1 EA200000836A EA200000836A EA200000836A1 EA 200000836 A1 EA200000836 A1 EA 200000836A1 EA 200000836 A EA200000836 A EA 200000836A EA 200000836 A EA200000836 A EA 200000836A EA 200000836 A1 EA200000836 A1 EA 200000836A1
Authority
EA
Eurasian Patent Office
Prior art keywords
imino
substituted
glucitive
didesoxy
derivatives
Prior art date
Application number
EA200000836A
Other languages
English (en)
Other versions
EA004705B1 (ru
Inventor
Ричард А. Мюллер
Мартин Л. Брайант
Ричард А. Пэртис
Original Assignee
Дж.Д.Серл Энд Ко.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/023,401 external-priority patent/US20030100532A1/en
Application filed by Дж.Д.Серл Энд Ко. filed Critical Дж.Д.Серл Энд Ко.
Publication of EA200000836A1 publication Critical patent/EA200000836A1/ru
Publication of EA004705B1 publication Critical patent/EA004705B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

В заявке описаны способы и композиции, предназначенные для лечения инфекций, вызываемых вирусом гепатита у млекопитающих, прежде всего у людей. Эти способы включают (1) введение N-замещенных 1,5-дидезокси-1,5-имино-D-глюцитных производных индивидуально или в сочетании с нуклеозидными антивирусными агентами, нуклеотидными антивирусными агентами и их смесями или с иммуномодулирующими/иммуностимулирующими агентами или (2) введение N-замещенных 1,5-дидезокси-1,5-имино-D-глюцитных производных индивидуально или в сочетании с нуклеозидными антивирусными агентами, нуклеотидными антивирусными агентами или их смесями, и с иммуномодулирующими/иммуностимулирующими агентами.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200000836A 1998-02-12 1999-02-12 Применение n-замещенных 1,5-дидезокси-1,5-имино-d-глюцитных производных для лечения инфекций, вызываемых вирусами гепатита EA004705B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7450898P 1998-02-12 1998-02-12
US09/023,401 US20030100532A1 (en) 1997-02-14 1998-02-12 Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
PCT/US1999/001874 WO1999040916A1 (en) 1998-02-12 1999-02-12 Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections

Publications (2)

Publication Number Publication Date
EA200000836A1 true EA200000836A1 (ru) 2001-04-23
EA004705B1 EA004705B1 (ru) 2004-06-24

Family

ID=26697090

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200000836A EA004705B1 (ru) 1998-02-12 1999-02-12 Применение n-замещенных 1,5-дидезокси-1,5-имино-d-глюцитных производных для лечения инфекций, вызываемых вирусами гепатита

Country Status (16)

Country Link
US (2) US6809083B1 (ru)
EP (1) EP1061922B9 (ru)
JP (1) JP2002502875A (ru)
KR (1) KR20010040937A (ru)
AT (1) ATE331515T1 (ru)
AU (2) AU762125B2 (ru)
BR (1) BR9907882A (ru)
CA (1) CA2319713C (ru)
DE (1) DE69932154T2 (ru)
EA (1) EA004705B1 (ru)
ES (1) ES2272054T3 (ru)
ID (1) ID27290A (ru)
MY (1) MY122185A (ru)
TR (1) TR200002323T2 (ru)
TW (1) TWI222867B (ru)
WO (1) WO1999040916A1 (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100532A1 (en) * 1997-02-14 2003-05-29 Gary S. Jacob Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
WO1999040916A1 (en) 1998-02-12 1999-08-19 G.D. Searle & Co. Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
US6689759B1 (en) 1998-02-12 2004-02-10 G. D. Searle & Co. Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy
WO2000047198A2 (en) * 1999-02-12 2000-08-17 G.D. Searle & Co. Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
JP2003505501A (ja) * 1999-02-12 2003-02-12 ジー・ディー・サール・アンド・カンパニー 肝炎ウィルス感染の処置のためのグルカミン化合物
US7816560B1 (en) 1999-08-10 2010-10-19 Thomas Jefferson University Long chain n-alkyl compounds and oxa-derivatives thereof
EP1261339A1 (en) * 2000-02-14 2002-12-04 Pharmacia Corporation Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
AU2013203966B2 (en) * 2000-05-23 2016-05-19 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus
MXPA02011691A (es) 2000-05-26 2004-05-17 Idenix Cayman Ltd Metodos y composiciones para el tratamiento de flavivirus y pestivirus.
US20050053625A1 (en) * 2001-10-30 2005-03-10 Block Timothy M Method of treating viral infections
WO2006085141A2 (en) * 2004-08-13 2006-08-17 Migenix Inc. Compositions and methods for treating or preventing hepadnaviridae infection
BRPI0613221A2 (pt) * 2005-06-08 2010-12-28 Amicus Therapeutics Inc furanose cristalina e método para produzir uma furanose cristalina
BRPI0613224A2 (pt) * 2005-06-08 2010-12-28 Amicus Therapeutics Inc método para estabilizar um açúcar triflatado, método para aumentar o rendimento da reação de um produto de açúcar e composição de açúcar triflatado estabilizada
BRPI0613222A2 (pt) * 2005-06-08 2010-12-28 Amicus Therapeutic Inc método para purificação de um açúcar bruto contendo nitrogênio e método para purificar d-l-deoxigalactonojirimicina bruta (dgj)
US7473683B2 (en) 2005-09-14 2009-01-06 The Board Of Trustees Of The Leland Stanford Junior University Nonpolar thymidine analogs
US8975280B2 (en) * 2006-05-24 2015-03-10 The Chancellor, Masters And Scholars Of The University Of Oxford Deoxynojirimycin and D-arabinitol analogs and methods of using
JP2009545621A (ja) 2006-08-02 2009-12-24 ユナイテッド セラピューティクス コーポレーション ウィルス感染症のリポソーム処置
US8097728B2 (en) * 2007-04-30 2012-01-17 Philadelphia Health & Education Corporation Iminosugar compounds with antiflavirus activity
CN102046151A (zh) * 2008-03-26 2011-05-04 牛津大学 靶向内质网的脂质体
EP2398321B1 (en) 2009-02-23 2015-11-25 United Therapeutics Corporation Iminosugars and methods of treating viral diseases
KR20120059447A (ko) * 2009-03-27 2012-06-08 더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드 콜레스테롤 수준 저하 리포좀
KR101463661B1 (ko) 2009-06-12 2014-11-19 유나이티드 세러퓨틱스 코오포레이션 면역당 및 분야바이러스 및 토가바이러스 질환의 치료 방법
JP5575246B2 (ja) * 2009-09-04 2014-08-20 ユナイテッド セラピューティクス コーポレイション ポックスウイルス感染の治療方法
WO2013184780A1 (en) 2012-06-06 2013-12-12 Unither Virology, Llc Novel iminosugars and their applications
BR112017008898B1 (pt) 2014-11-05 2022-11-29 Emergent Virology Llc Compostos de iminoaçúcares, suas composições farmacêuticas e usos dos mesmos para tratar doenças virais
SG11201805729SA (en) * 2016-01-08 2018-08-30 Arbutus Biopharma Corp Therapeutic compositions and methods for treating hepatitis b

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU33730B (en) 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
GB1555654A (en) 1977-06-25 1979-11-14 Exxon Research Engineering Co Agricultural burner apparatus
US4065562A (en) 1975-12-29 1977-12-27 Nippon Shinyaku Co., Ltd. Method and composition for reducing blood glucose levels
US4012448A (en) 1976-01-15 1977-03-15 Stanford Research Institute Synthesis of adriamycin and 7,9-epiadriamycin
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
GB2020278B (en) 1978-05-03 1983-02-23 Nippon Shinyaku Co Ltd Moranoline dervitives
JPS5562004A (en) 1978-11-02 1980-05-10 Kureha Chem Ind Co Ltd Control agent against plant viral disease
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
DE3049446A1 (de) 1980-12-30 1982-07-29 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von 1,5-didesoxy-1,5-imino-d-glucitol und dessen n-derivaten
ZA822995B (en) 1981-05-21 1983-12-28 Wyeth John & Brother Ltd Slow release pharmaceutical composition
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
EP0252962B1 (en) 1985-12-23 1995-08-23 Fred Hutchinson Cancer Research Center Regulating retroviral replication, infection, and pathogenesis
GB2186485B (en) 1986-02-13 1988-09-07 Ethical Pharma Ltd Slow release formulation
DE3611841A1 (de) 1986-04-09 1987-10-15 Bayer Ag Verfahren zur herstellung von 1-desoxynojirimycin und dessen n-derivaten
PT89266B (pt) 1987-12-21 1993-11-30 Monsanto Co Metodo para a inibicao de virus da imunodeficiencia humana utilizando um derivado n-n-butilo de desoxinojirimicina
US4849430A (en) * 1988-03-09 1989-07-18 Monsanto Company Method of inhibiting virus
FI101344B1 (fi) 1988-03-31 1998-06-15 Tanabe Seiyaku Co Menetelmä valmistaa valmiste, josta kontrolloidusti vapautuu farmaseuttisesti aktiivista ainetta
US5041441A (en) 1988-04-04 1991-08-20 The Regents Of The University Of Michigan Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol
EP0350012A3 (en) 1988-07-08 1990-09-05 Meiji Seika Kaisha Ltd. Antiviral composition
US5144037A (en) 1988-11-03 1992-09-01 G. D. Searle & Co. 1,5-dideoxy-1,5-imino-d-glucitol derivatives
US5221746A (en) * 1988-11-03 1993-06-22 G. D. Searle & Co. 1,5-dideoxy-1,5-imino-D-glucitol derivatives
US5310745A (en) 1988-11-03 1994-05-10 G. D. Searle & Co. Antiviral compounds
US5003072A (en) * 1988-11-03 1991-03-26 G. D. Searle & Co. 1,5-dideoxy-1,5-imino-D-glucitol derivatives
US4957926A (en) 1988-12-22 1990-09-18 Monsanto Company Method of treating herpesviruses
US5011829A (en) 1989-06-02 1991-04-30 G. D. Searle & Co. Pharmaceutical composition and method of inhibiting virus
US5030638A (en) * 1990-02-26 1991-07-09 G. D. Searle & Co. Method of antiviral enhancement
DE4009561A1 (de) 1990-03-24 1991-09-26 Bayer Ag Neue desoxynojirimycinderivate, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
US5536732A (en) 1990-04-27 1996-07-16 Merrell Pharmaceuticals Inc. N-derivatives of 1-deoxy nojirimycin
US5151519A (en) 1990-05-07 1992-09-29 G. D. Searle & Co. Process for the preparation of 1,5-(alkylimino)-1,5-dideoxy-d-glucitol and derivatives thereof
EP0477160B1 (en) 1990-09-20 1996-04-24 Monsanto Company Process for producing N-substituted-1-deoxynojirimycin
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5190765A (en) 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
IL105090A (en) 1992-03-18 1998-08-16 Us Bioscience Acid N) phosphonoacetyl (Aspartic L in a broad spectrum antiviral agent
ZA931934B (en) 1992-03-18 1993-03-18 Us Bioscience Compostitions of N-(phosphonoacetyl)-L-aspartic acid and methods of their use as broad spectrum antivirals
US5258518A (en) 1992-04-01 1993-11-02 G. D. Searle & Co. 2-substituted tertiary carbinol derivatives of deoxynojirimycin
US5331096A (en) 1992-04-01 1994-07-19 G. D. Searle & Co. 2- and 3-sulfur derivatives of 1,5-iminosugars
WO1994004546A1 (fr) 1992-08-14 1994-03-03 Nippon Shinyaku Co., Ltd. Derive de moranoline
FR2700267B1 (fr) 1993-01-13 1995-03-17 Oreal N-acyl amino déoxy alditols, et leur utilisation dans des compositions cosmétiques ou dermopharmaceutiques.
DE69419601T2 (de) 1993-03-17 1999-12-02 Kao Corp., Tokio/Tokyo Aminderivate und sie enthaltende dermatologische zubereitungen
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
WO1995006061A1 (en) 1993-08-20 1995-03-02 G.D. Searle & Co. Retroviral protease inhibitors and combinations thereof
US6093702A (en) * 1993-12-20 2000-07-25 The United States Of America As Represented By The Department Of Health And Human Services Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread
DE69421828T2 (de) * 1994-01-13 2000-04-20 G.D. Searle & Co. Verwendung von 1,5-dideoxy-1,5-imino-d-glucitol n-alkylderivaten zur behandlung von hepatitis b infektionen
WO1995022975A1 (en) 1994-02-25 1995-08-31 G.D. Searle & Co. Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus
US5451679A (en) 1994-03-08 1995-09-19 G. D. Searle & Co. 2-chloro and 2-bromo derivatives of 1,5-iminosugars
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
FR2731150B1 (fr) 1995-03-03 1997-04-18 Oreal Utilisation de composes amphiphiles en tant qu'agent epaississant de milieux non aqueux
US5763470A (en) 1995-06-07 1998-06-09 Sugen Inc. Benzopyran compounds and methods for their use
WO1997000881A1 (fr) 1995-06-22 1997-01-09 Nippon Shinyaku Co., Ltd. Derives de la moranoline
AU6169298A (en) * 1997-02-14 1998-09-08 G.D. Searle & Co. Use of (n)-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combinationtherapy for treating hepatitis virus infections
CN1290168A (zh) 1997-12-11 2001-04-04 牛津大学院长校长专家委员会 膜相关病毒复制的抑制
WO1999040916A1 (en) 1998-02-12 1999-08-19 G.D. Searle & Co. Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections

Also Published As

Publication number Publication date
US6809083B1 (en) 2004-10-26
AU2003248024A1 (en) 2003-10-30
DE69932154D1 (de) 2006-08-10
KR20010040937A (ko) 2001-05-15
ES2272054T3 (es) 2007-04-16
EP1061922B1 (en) 2006-06-28
BR9907882A (pt) 2000-10-17
ATE331515T1 (de) 2006-07-15
CA2319713C (en) 2012-06-26
CA2319713A1 (en) 1999-08-19
MY122185A (en) 2006-03-31
WO1999040916A1 (en) 1999-08-19
DE69932154T2 (de) 2007-05-31
ID27290A (id) 2001-03-22
TR200002323T2 (tr) 2000-12-21
TWI222867B (en) 2004-11-01
EP1061922B9 (en) 2007-03-07
US20050267153A1 (en) 2005-12-01
AU762125B2 (en) 2003-06-19
AU2759599A (en) 1999-08-30
EP1061922A1 (en) 2000-12-27
JP2002502875A (ja) 2002-01-29
EA004705B1 (ru) 2004-06-24

Similar Documents

Publication Publication Date Title
EA200000836A1 (ru) Применение n-замещенных 1,5-дидезокси-1,5-имино-d-глюцитных производных для лечения инфекций, вызываемых вирусами гепатита
DE60039729D1 (de) N-(8,8,8-Trifluorooctyl)-1,5-dideoxy-1,5-imino-D-glucitol zur Behandlung von Hepatitis-Virus-Infektionen
TW200500374A (en) 2' and 3' -nucleoside produrgs for treating flavivridae infections
KR0179637B1 (en) Diaromatic substituted compounds as anti-hiv-1 agents
DE69830241D1 (de) Verwendung von n-substituierten 1,5-dideoxy-1,5-imino-d-glucitol verbindungen in der kombinationstherapie der vom hepatitisvirus verursachten infektionen
MXPA04012779A (es) Profarmacos de 2'- y 3'-nucleosido para tratar infecciones por flaviviridae.
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
EA200201262A1 (ru) Композиции для лечения флавивирусных и пестивирусных инфекций и способы их применения
EA200201279A1 (ru) Способы и композиции для лечения вирусного гепатита c
PT1066269E (pt) Derivados de 1,3,5-triazina trissubstrituidos para o tratamento de infeccoes por hiv
NO20045247L (no) Nukleosidderivater for behandling av hepatitt C-virusinfeksjon
ATE491459T1 (de) Modifizierte nukleoside zur behandlung von virusinfektionen und abnormaler zellulärer proliferation
EA200300819A1 (ru) Производные нуклеозидов в качестве ингибиторов рнк-зависимой рнк вирусной полимеразы
MXPA06000418A (es) Derivados de ariltiourea sustituida utiles como inhibidores de duplicacion viral.
WO2006101538A3 (en) Andrographolide derivatives to treat viral infections
ES2140652T3 (es) Uso de n-alquil-derivados de 1,5-didesoxi-1,5-imino-d-glucitol para el tratamiento de infecciones por el virus de la hepatitis b.
WO2001008672A3 (en) Glucamine compounds for treating hepatitis virus infections
DK0610078T3 (da) Cytotoksisk og antiviral forbindelse.
WO2004052905A3 (en) Antiviral nucleoside derivatives
AR024537A1 (es) Combinacion sinergica para el tratamiento de enfermedades mediadas virales
AR019532A1 (es) COMPOSICIoN FARMACÉUTICA DEL COMPUESTO 1,5-DIDEOXI-1,5-IMIN-D-GLUCITOL N-SUSTITUIDO
AU2003302275A8 (en) Bicyclic carbohydrate compounds useful in the treatment of infections caused by flaviviridae sp., such as hepatitis c and bovine viral diarrhea viruses
ECSP993176A (es) Nuevos compuestos y composiciones antibacterianas

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU